Loading... Please wait.
Perfil da Empresa
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.
Fonte:
Cofisem
-
Última atualização:
10 Jan 2025
Principais Executivos
| Chief Executive Officer | Gavin Spencer | ||||
| Chief Financial Officer | Sandrine Gestin | ||||
| Chief Human Resources Officer | Sandrine Gestin | ||||
| Chief Scientific Officer | Doug Hubatsch | ||||
| Chief Business Development Officer | Emmet Purtill | ||||
| Fonte: Cofisem - Última atualização: 10 Jan 2025 | |||||
Números principais
| Millenium | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Net sales | 6.903 | 3.271 | 7.233 | 12.907 | 6.855 |
| Consumed purchases | 18.406 | ||||
| Labour costs | 2.503 | ||||
| Operating profit | -17.056 | ||||
| Income tax | -478 | ||||
| Net income | -20.881 | -27.759 | -43.761 | -18.098 | -18.922 |
| Fiscal year end | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | French_GAAP | IFRS | IFRS | IFRS | IFRS |
| Income from ordinary activities | 3.271 | 7.233 | 12.907 | 6.855 | |
| Operating income | -34.061 | -46.010 | -6.760 | -18.332 | |
| Cost of financial indebtedness net | 1.246 | 4.837 | 8.188 | 5.100 | |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income (Group share) | -27.759 | -43.761 | -18.098 | -18.922 | |
| Fonte: Cofisem - Última atualização: 10 Jan 2025 | |||||
Informação Acionistas
Morada
Nicox SA
Sundesk Sophia Antipolis, Bâtiment C Emerald Square Rue Evariste Galois
FR-06410
Biot
France
Número de telefone:
+33 (0)4 97 24 53 00
Fonte:
Cofisem
-
Última atualização:
10 Jan 2025